| Objective:1、Explore miR-138-5p in triple-negative breast cancer tissues and adjacent normal breast tissues and its relation with clinicopathologic factors;2.Research the effect of miR-138-5p on triple-negative breast cancer cells and explore the proper mechanism.Method:1.Using RT-PCR explore the expression of miR-138-5p in breast cancer tissues and the adjacent tissues.2.Using the immunohistochemical method to detect the miR-138-5p expression in patients with breast cancer and compare with clinical stage,grade,age,Ki67 etc.3.use the technology of cell transfection to overexpress miR-138-5p in MDA-MB-231 breast cancer cells;use flow cytometry to detect the proliferation and apoptosis of breast cancer cells.4.Use Western Blotting to test the change of the protein level of PD-L1 before and after the transfection.Results:1.Compared to the related normal tissues,the expression of miR-138-5p was significantly lower in most tumors in patients with triple-negative breast 45 cancer.2.The expression of miR-138-5p was related with the clinical stage,grade,Ki-67 and so on;3.The expression of miR-138-5p increased after transfection in human breast cancer MDA-MB-231 cells;breast cancer cell proliferation was inhibited and the apoptosis rate of the MDA-MB-231 breast cancer cells increased.4.The aberrant increased protein level of PD-L1 was reversed by miR-138-5p transfection.Conclusions:Decrease of miR-138-5p was found in most patients with triple-negative breast cancer tissues,and the decreased expression of miR-138-5p was found to be a statistically significant with negative prognostic factor.Selective miR-138-5p overexpression by transfection resulted in the inhibition of tumor cell growth in MDA-MB-231 cells and,also miR-138-5p-overexpression could reduce the protein level of PD-L1.Our findings suggest that miR-138-5p plays a critical role in triple-negative breast cancer progression and may serve as a novel therapeutic target in breast cancer. |
PDF Full Text Request